Javier Jurado, MD
Cardiovascular Disease · Evansville, INNPI 1104099142
Payments from drug & device makers
Across 54 payments — averaging $475.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Boehringer Ingelheim$8K
- Lilly USA, LLC$990
- Abbott$459
- Edwards Lifesciences$174
- Pfizer$155
- plus $330 from 9 others
What the payments were for
- Speaking & faculty fees$23,29091%
- Travel & lodging$7833%
- Food & beverage$1,5936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $15,394 |
| Boehringer Ingelheim | 9 | $8,163 |
| Lilly USA, LLC | 2 | $990 |
| Abbott | 7 | $459 |
| Edwards Lifesciences | 1 | $174 |
| Pfizer | 2 | $155 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $64 |
| Intuitive Surgical | 1 | $60 |
| Alnylam Pharmaceuticals Inc. | 1 | $44 |
| Abiomed | 1 | $43 |
| Astellas Pharma US Inc | 3 | $40 |
| Novartis | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$15,050
- JARDIANCE$9,142
- SAPIEN 3 Ultra RESILIA$174
- CardioMEMS HF System$144
- HeartMate$136
- VYNDAQEL$112
How this compares
$25,666 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 85 | $2,447,753 |
| VyndaqelTafamidis Meglumine | 18 | $623,366 |
| FarxigaDapagliflozin Propanediol | 761 | $493,893 |
| JardianceEmpagliflozin | 587 | $458,542 |
| EntrestoSacubitril/Valsartan | 379 | $324,233 |
| EliquisApixaban | 244 | $216,888 |
| Repatha SureclickEvolocumab | 102 | $85,032 |
| XareltoRivaroxaban | 82 | $68,822 |
| VascepaIcosapent Ethyl | 88 | $33,648 |
| Praluent PenAlirocumab | 43 | $24,093 |
| DapagliflozinDapagliflozin Propanediol | 36 | $17,270 |
| CorlanorIvabradine Hcl | 17 | $9,912 |
| Ranolazine ErRanolazine | 93 | $8,860 |
| NexletolBempedoic Acid | 15 | $5,921 |
| Metoprolol Succinate | 561 | $5,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $155 | $3,288,008347 claims |
| AstraZenecaFarxiga | $15,394 | $493,893761 claims |
| Boehringer IngelheimJardiance | $8,163 | $458,542587 claims |
| NovartisEntresto | $32 | $324,233379 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Evansville
- Douglas ShefferEvansville$138K
- John McGintyRichmond$3.7M
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.